Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

ISIS PHARMACEUTICALS, INC. (ISIS)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 457 M
EBIT 2017 33,4 M
Net income 2017 -10,3 M
Finance 2017 310 M
Yield 2017 -
Sales 2018 516 M
EBIT 2018 33,3 M
Net income 2018 25,8 M
Finance 2018 434 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 112,47
EV / Sales2017 13,0x
EV / Sales2018 11,2x
Capitalization 6 222 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology.It operates its business through the Ionis Core and Akcea Therapeutics segments.The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline... 
Sector
Biotechnology & Medical Research
Calendar
02/27 | 01:00pmEarnings Release
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
02/22IONIS PHARMACEUTICALS INC : annual earnings release
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/15IONIS PHARMACEUTICALS : to Hold 2017 Financial Results Conference Call
AQ
02/14IONIS PHARMACEUTICALS : The New England Journal of Medicine Publishes SPINRAZA® ..
BU
02/13IONIS PHARMACEUTICALS : to Hold 2017 Financial Results Conference Call
PR
01/30AKCEA THERAPEUTICS : AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With ..
AQ
01/19IONIS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
01/19IONIS PHARMACEUTICALS : ' Inotersen NDA Accepted for Priority Review by the FDA
AQ
01/08AKCEA THERAPEUTICS : Initiates Phase 2b Study of -APOCIII-LRx in Patients with H..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
12:30pSANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
ISIS PHARMACEUTICALS - 2014
A resistance as obstacle
SELL
More Strategies
News from SeekingAlpha
2015Game Plan For The Week - Cramer's Mad Money (12/18/15) 
2015PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr.. 
2015Isis Pharma has had enough, name changed to Ionis Pharmaceuticals 
2015Bear Afoot? No Recession Needed For A Possible Sighting 
2015PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui.. 
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 14
Average target price 57,5 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
Brett P. Monia Chief Operating Officer
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
B. Lynne Parshall Director
Joseph H. Wender Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%6 222
CELLTRION, INC.--.--%34 966
IQVIA HOLDINGS INC1.90%20 749
LONZA GROUP-6.95%19 587
INCYTE CORPORATION-10.56%17 877
NEKTAR THERAPEUTICS44.76%13 613